Teleflex' Urolift System shows positive data in five studies to treat enlarged prostate

• Teleflex (NYSE:TFX) said results from several research studies showed the safety and efficacy of its product, UroLift System, to treat men with enlarged prostate.
• The company said pooled outcomes of over 300 subjects from five studies revealed most men shifted to lower international prostate symptom score (IPSS) symptom severity after treatment with Prostatic Urethral Lift.